KRAS G12C MUTANT SOLID TUMORS
Clinical trials for KRAS G12C MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for KRAS G12C MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, given alone or with other treatments, for people with advanced solid tumors that have a specific change in the KRAS gene (G12C). The goal is to find safe doses and see if the drug can shrink tumors. About 74 adults with lung or colorecta…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 06, 2026 16:03 UTC
-
New drug combo targets tough cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, alone or with other medicines, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and can shrink tumors. About 344 adults whose cancer has not responded to standard treatm…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 05, 2026 11:56 UTC